Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Pharma
ASH: GSK details Blenrep's survival win against J&J's Darzalex
Blenrep cut the risk of death by 42% compared with Darzalex in the meds' respective combinations with Vd in second- or later-line multiple myeloma.
Angus Liu
Dec 9, 2024 1:30pm
AZ's Enhertu, Akeso's bispecifics win reimbursement in China
Dec 4, 2024 12:52pm
Kelun's Merck-partnered TROP2 ADC snags first nod in China
Nov 27, 2024 10:56am
Merck and BioNTech's I-O bispecific buys—Fierce Pharma Asia
Nov 15, 2024 8:20am
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
Nov 14, 2024 9:24am
Daiichi enlists Alteogen for subcutaneous Enhertu in $300M deal
Nov 8, 2024 11:19am
